IOIsmael Olmos

Ismael Olmos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ismael Olmos has a total of 221 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Optimization of Clozapine Treatment

    by Ismael Olmos, Carina Ricciardi, Mauricio Mato, Natalia Guevara, Sabrina Acuña, Cecilia Maldonado, Marta Vázquez, Mauricio Md Toledo, Clara Bsc Menéndez, Valentina Msc Blanco, et al.

    Purpose/Background: Clozapine is the recommended drug for treatment-resistant schizophrenia. Drug response could be affected by numerous factors such as age, sex, body mass index, co-medication, consumption of xanthine-containing beverages, smoking, and genetic variants of the enzymes involved in clozapine metabolism (CYP1A2, CYP3A4, and, to a lesser extent, CYP2C19 and CYP2D6). This study evaluated genetic and nongenetic variables that may affect clozapine plasma concentrations in Uruguayan patients with schizophrenia. Methods/Procedures: Demographic data including sex, age, ethnicity, body weight, smoking habit, concomitant medication, and xanthine consumption were collected through a data collection form. Clozapine and norclozapine concentrations were determined using an HPLC system equipped with a UV detector. Genetic variants were determined through next-generation sequencing using Illumina sequencing technology and a panel of DNA probes. Findings/Results: Fifty patients were included in the study. After evaluation, only tobacco use and obesity had a significant impact on clozapine exposure (P < 0.05). The high prevalence of the genetic variant CYP1A2*1F may account for the significant impact that tobacco smoking has on clozapine concentrations. Some common adverse effects observed in this study depend on clozapine plasma concentrations, such as constipation and sialorrhea. Implications/Conclusions: These types of studies provide the clinician with tools to optimize clozapine therapy, attempting to use the minimum effective dose and attenuating the burden of concentration-dependent adverse reactions.


  • Open Access

    Tasas de suicidio y concentración de litio en agua corriente en Rocha y Montevideo

    by María Alcira Frontini, Ismael Olmos, Gonzalo Giraldez, Fabián Lara

    El suicidio es un fenómeno que además de las pérdidas humanas que involucra, repercute negativamente en familiares y allegados, produciendo a su vez enormes gastos en el sistema sanitario. En Uruguay, la tasa de suicidio no solo ha experimentado un aumento sostenido, representando una preocupación constante para las autoridades, sino que suele ser una de la más altas de Latinoamérica, en 2022 fue de 23,08 cada 100.000 habitantes. Reconociendo que el suicidio es un fenómeno multifactorial grave, diversos estudios han indagado sobre la posible correlación entre la presencia de litio en agua corriente y tasas de suicidio, habiéndose observado una relación inversa, lo que permitiría considerar el litio como eventualmente protector de la conducta suicida. El presente estudio pretende abordar dicha correlación en los departamentos de Rocha y Montevideo, de Uruguay. Los resultados obtenidos no son concluyentes. En cuanto a las concentraciones de litio presentes en agua corriente, en general son menores a las señaladas en otros estudios como protectoras (30 µ/L). Es necesario profundizar en este eje de discusión, como en otros, para obtener un diagnóstico más detallado de este complejo y sentido fenómeno.

  • An expert review of clozapine in Latin American countries: Use, monitoring, and pharmacovigilance

    by Trino Baptista, Mariano Motuca, Ana Serrano, Alirio Perez Lo Presti, Alberto Fernandez-Arana, Ismael Olmos, Albis Pabon, Juan Genaro Ayala Yepez, Gabriel de Jesus Alejo Galarza, Nuria Monserrat Rivera Ramirez, et al.


  • Clozapine safety monitoring and related research in psychiatry and neurology in South America: A scoping review

    by Trino Baptista, Ana Serrano, Alirio Perez Lo Presti, Alberto Fernandez-Arana, Helio Elkis, Mariano Motuca, Ismael Olmos, Georgios Schoretsanitis


  • Exploring low clozapine C/D ratios, inverted clozapine-norclozapine ratios and undetectable concentrations as measures of non-adherence in clozapine patients

    by Can-Jun Ruan, Ismael Olmos, Carina Ricciardi, Georgios Schoretsanitis, Philippe D. Vincent, A. Elif Anıl Yağcıoğlu, Chin B. Eap, Trino Baptista, Scott R. Clark, Emilio Fernandez-Egea, et al.


  • Open Access

    AB1236 OSTEOPOROSIS AND FRACTURES IN PATIENTS UNDERGOING CHRONIC CORTICOSTEROID THERAPY

    by J. E. Oller Rodríguez, E. Grau García, C. Riesco Barcena, A. V. Huaylla Quispe, A. M. Torrat Noves, D. Ramos Castro, P. Muñoz Martinez, L. Mas Sanchez, S. Leal Rodriguez, I. Cánovas Olmos, et al.

    Background Glucocorticoids are widely used for the treatment of various rheumatic diseases and are one of the major risk factors for bone fragility associated fractures. However, beyond randomized clinical trials, there is little evidence in actual clinical practice. Objectives Our aim is to evaluate the appearance of osteoporosis and fractures in patients undergoing corticosteroid therapy. Methods We performed an observational retrospective descriptive study with Vasculitis (several subtypes) or Polymyalgia Rheumatica (PMR) patients diagnosed, who had received corticosteroid regimens with doses of at least 5 mg/day of prednisone (or equivalent) for a period of not less than 3 months, and in which the appearance of fractures was monitored for the next 2 years. Results We included 234 patients (62.4% females) with a mean age at the onset of corticosteroids of 75.8 years and mean duration corticosteroid regimens of 58 months. The most represented disease was PMR, with 183 patients (78.2%), followed by Large Vessel Vasculitis (12.4%), ANCA positive Small Vessel Vasculitis (4.3%), ANCA negative Small Vessel Vasculitis (3.4%), with a lower proportion of Medium Vessel vasculitis and other diseases such as Relapsing Polychondritis. Furthermore, 29 patients (12.39%) had previous fragility fractures, while 32 patients (13.68%) suffered one or more fractures after the start of corticosteroid therapy, being hip its most frequent location (4.7%), followed by vertebrae (3.8%). Likewise, the mean duration of corticosteroid treatment until the onset of new fractures was 4.5 months. Even without reaching statistical significance, we observed a greater age (80.5 years), a higher presence of the female gender (81.25%) and a previous fracture (18.75%) in patients with new fractures. In addition, 32.91% of patients had densitometric osteoporosis at the beginning of corticosteroid therapy. Comparison between different therapeutic options We observed an association between fractures and zoledronate treatment (P=0.012), and a tendency for ibandronate (P=0.07). The discreet entity of these differences could be explained by the statistical effect produced by the small number of new fractures, taking into account, moreover, the fact that in our Rheumatology Department we systematically carry out a fracture risk assessment to decide whether and when to start the treatment, and also prescribing more powerful therapeutic options to patients at higher risk of fracture. Finally, we did not observe significant differences in fracture-free time among the most frequent therapeutic options. Conclusion We observed a tendency to have a higher frequency of fractures in patients with previous fractures, older age and female gender. Less quantitative prevention of fractures was observed in patients with zoledronate and ibandronate, with no clear differences in fracture-free time. REFERENCES: NIL. Acknowledgements: NIL. Disclosure of Interests None Declared.

  • Clozapine ultrarapid metabolism during weak induction probably exists but requires careful diagnosis. A literature review, five new cases and a proposed definition

    by Georgios Schoretsanitis, A. Elif Anıl Yağcıoğlu, Can-Jun Ruan, Chin B. Eap, Espen Molden, Trino Baptista, Scott R. Clark, Emilio Fernandez-Egea, Se Hyun Kim, Hsien-Yuan Lane, et al.


  • Escaping the Long Shadow Cast by Agranulocytosis

    by Jose de Leon, Manuel Arrojo-Romero, Hélène Verdoux, Can-Jun Ruan, Georgios Schoretsanitis, Christopher Rohde, Dan Cohen, Peter F.J. Schulte, Se Hyun Kim, Robert O. Cotes, et al.

    Purpose/Background: A recent article in this journal presented a US perspective regarding the modernization of clozapine prescription and proposed an escape from the long shadow cast by agranulocytosis. Methods: Here, an international group of collaborators discusses a point of view complementary to the US view by focusing on worldwide outcomes of clozapine usage that may be uneven in terms of frequency of clozapine adverse drug reactions. Findings/Results: Studies from the Scandinavian national registries (Finland and Denmark) did not find increased mortality in clozapine patients or any clear evidence of the alleged toxicity of clozapine. Data on clozapine-associated fatal outcomes were obtained from 2 recently published pharmacovigilance studies and from the UK pharmacovigilance database. A pharmacovigilance study focused on physician reports to assess worldwide lethality of drugs from 2010 to 2019 found 968 clozapine-associated fatal outcomes in the United Kingdom. Moreover, the United Kingdom accounted for 55% (968 of 1761) of worldwide and 90% (968 of 1073) of European fatal clozapine-associated outcomes. In a pharmacovigilance study from the UK database (from 2008 to 2017), clozapine was associated with 383 fatal outcomes/year including all reports from physicians and nonphysicians. From 2018 to 2021, UK clozapine-associated fatal outcomes increased to 440/year. Implications/Conclusions: The interpretation of fatal outcomes in each country using pharmacovigilance databases is limited and only allows gross comparisons; even with those limitations, the UK data seem concerning. Pneumonia and myocarditis may be more important than agranulocytosis in explaining the uneven distribution of fatal outcomes in clozapine patients across countries.


  • Open Access

    Seguridad del paciente Análisis de la prescripción en adultos mayores de una policlínica de salud mental del Hospital Vilardebó, Uruguay

    by Ismael Olmos, Diana Angulo, Mauricio Mato, Carina Ricciardi, Mauricio Toledo, Marta Vázquez

    Introducción: los pacientes con 65 años o más, por su condición fisiológica, tienen mayor probabilidad de estar expuestos a reacciones adversas a medicamentos. Algunos riesgos están asociados a la carga anticolinérgica de la medicación, y otros al perfil de seguridad de cada uno de los fármacos. Objetivo: realizar un análisis de los tratamientos farmacológicos para los pacientes ≥65 años y su posible implicancia en la clínica, por los riesgos potenciales debido a reacciones adversas. Método: se realizó un estudio descriptivo, transversal, observacional, naturalístico, del tratamiento farmacológico de los pacientes ≥65 años de la policlínica del Hospital Vilardebó, entre mayo y agosto de 2021. Se calculó la carga anticolinérgica de los tratamientos y se efectuó una comparación de dicha carga con la de una muestra de pacientes menores de 65 años. Resultados: 356 pacientes (83,0%) ≥65 años tenían un riesgo alto de tener algún efecto por su carga anticolinérgica y este riesgo fue similar a los pacientes menores de 65 años. Un total de 344 pacientes estaban en tratamiento con alguna benzodiazepina, destacándose el uso de flunitrazepam (47,6%) y clonazepam (32,6%). A 289 pacientes (67,4%) se le prescribió algún antipsicótico y nueve pacientes estaban con más de dos antipsicóticos. Dos pacientes estaban en tratamiento con imipramina y 49 pacientes recibían algún antiparkisoniano. Conclusiones: los pacientes mayores de 65 años están expuestos a riesgos altos de padecer reacciones adversas a medicamentos como consecuencia de una alta carga anticolinérgica (similar a la de la población más joven estudiada) y de una acentuada polifarmacia. Además, se deberían evitar algunas prácticas, como la prescripción de ciertos tipos de benzodiacepinas, así como minimizar el uso de imipramina y antiparkisonianos. Es necesario buscar estrategias de formación que disminuyan o minimicen este potencial riesgo que repercute adversamente en la salud de los pacientes.